Loading
EORTC 22033 asked whether temozolomide could replace radiotherapy as the first treatment for high-risk low-grade glioma and found no difference in progression-free survival, with the molecular subtype mattering more than the choice of treatment.
EORTC 22033-26033 randomised 477 adults with high-risk low-grade glioma to 50.4 Gy radiotherapy or dose-dense temozolomide for up to a year. Median progression-free survival was 46 months with radiotherapy and 39 months with temozolomide (hazard ratio 1.16, not significant); IDH-mutant tumours without 1p/19q co-deletion did better with radiotherapy, and health-related quality of life did not differ (Baumert and colleagues, Lancet Oncology 2016). Radiotherapy followed by chemotherapy (as in RTOG 9802) remains the standard.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, EORTC, Brain and spinal cord tumours (all types), Glioma & glioblastoma and the tag radiation-wave4.
Shares Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, Brain and spinal cord tumours (all types), Glioma & glioblastoma, IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares EORTC, IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares EORTC and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.
Shares IMRT / IGRT (modern external beam) and the tag radiation-wave4.